H.C. Wainwright Recommends EU Approval for Acadia's DAYBU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
The CHMP last week issued a positive re-examination opinion recommending EU approval for Acadia's DAYBU, or trofinetide, after narrowing the label to neurobehavioral symptoms of Rett syndrome and restricting the age range, with the decision based on Phase 3 LAVENDER trial results showing clinically meaningful improvements, H.C. Wainwright tells investors in a research note. The European Commission will now make the final decision, and potential orphan exclusivity could provide up to 10 years of protection if upheld, the firm, which has a Buy rating and $37 price target on Acadia shares, says.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACAD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 25.770
Low
23.00
Averages
31.17
High
40.00
Current: 25.770
Low
23.00
Averages
31.17
High
40.00
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acadia Appoints New Chief People Officer
- Executive Appointment: Acadia Pharmaceuticals announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6, aimed at advancing the company's global people and culture strategy to support its growth in the neurological and rare disease sectors.
- Extensive Industry Experience: Carl brings over 25 years of global HR leadership experience, having served as Senior Vice President at Merck, supporting a $50 billion global business, showcasing his capability in driving transformation within complex, science-driven organizations.
- Talent Strategy Leadership: During his tenure at Merck, Carl was responsible for global talent strategy and leadership development, successfully driving organizational capability shifts that included hiring over 10,000 employees annually, demonstrating his deep expertise in talent management.
- Strategic Culture Building: Carl expressed excitement about joining Acadia at this critical growth stage, looking forward to collaborating with the leadership team to strengthen company culture, develop talent, and support ongoing success while advancing innovation and patient care.
See More
U.S. Stocks Close Lower on Friday, Chipmakers Weigh on Market
- Market Decline: The S&P 500 and Nasdaq 100 fell by 0.05% and 1.09% respectively on Friday, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which could undermine investor confidence.
- Chipmaker Sell-off: The significant drop in Samsung Electronics and SK Hynix shares led to a more than 5% decline in South Korea's Kospi Index, triggering a global downturn in semiconductor stocks and exacerbating market uncertainty.
- Oil Price Impact: WTI crude oil prices fell over 3% to a four-month low on Friday, which helps lower inflation expectations and supports the stock market, but also reflects potential slowdowns in global economic growth.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward by 0.6 to 49.5, although still below the expected 50.0, indicating a cautious consumer outlook that may affect future spending.
See More
US Stock Market Under Pressure as Chip Stocks Plummet
- Market Weakness: The S&P 500 and Nasdaq 100 indices fell by 0.07% and 0.75%, respectively, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which may lead to declining investor confidence.
- Chip Stock Plunge: The significant sell-off of Samsung Electronics and SK Hynix caused the South Korean Kospi index to drop over 5%, triggering a global decline in chip stocks and exacerbating market uncertainty.
- Oil Price Decline Impact: WTI crude oil prices fell by more than 3%, easing inflation expectations and supporting stocks; however, the recovery of crude exports to 75% of pre-war levels may influence future market dynamics.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward to 49.5, although still below the expected 50.0, reflecting cautious consumer attitudes towards the economic outlook, which could affect retail and consumer-related stocks.
See More
Acadia's Daybue Receives Positive Recommendation in EU
- Drug Approval Progress: Acadia Pharmaceuticals' Daybue received a positive opinion from the CHMP upon reevaluation, recommending it for patients aged five and older with Rett syndrome; if approved by the European Commission, it would be the first treatment specifically for this rare condition in the region.
- Strong Market Reaction: Following the positive recommendation, Acadia's shares surged 15% on Friday, and if gains hold, it is on track for its best single-day performance since May 2025, indicating strong investor confidence in the drug's prospects.
- Clinical Trial Challenges: Despite showing some improvement in patients after 12 weeks of treatment, the CHMP's initial opinion in February deemed the benefits insufficiently significant and difficult to interpret, prompting Acadia to request a formal re-examination of the findings.
- Retail Investor Sentiment: Over the past 24 hours, retail sentiment around ACAD stock remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', and discussions surged 400% in the last week, reflecting optimism about Acadia's future potential.
See More
Acadia Pharmaceuticals Shares Surge 12.2% on Positive Drug News
- Strong Price Recovery: Acadia Pharmaceuticals saw its stock price surge 12.2% on Friday, bringing it close to its 52-week high, reflecting optimistic market sentiment regarding its future performance.
- New Market Opportunity: With the European Medicines Agency's recommendation, the Daybue drug is poised to become the first approved treatment for neurobehavioral symptoms of Rett syndrome, potentially opening new market avenues and driving sales growth.
- Solid Financial Performance: Acadia's Daybue and Nuplazid generated revenues of $101 million and $167 million respectively in Q1 2023, demonstrating the company's profitability and market potential in the rare disease sector.
- Investor Considerations: Despite the significant stock price increase, some investors may be concerned about short-term pullback risks, suggesting that risk-tolerant investors might wait for price stabilization before entering the market.
See More
Acadia Pharmaceuticals Shares Surge 12.2% on Positive Drug News
- Significant Market Potential: Acadia Pharmaceuticals focuses on rare diseases, where despite small market sizes, the lack of competition makes its potential revenue significant compared to its market cap of less than $5 billion, indicating a unique investment opportunity.
- Sales Growth: In the first fiscal quarter, Acadia's treatments Daybue and Nuplazid generated revenues of $101 million and $167 million respectively, reflecting a 20% year-over-year growth and showcasing the company's strong performance in the rare disease treatment sector.
- EU Approval Recommendation: The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Daybue for treating neurobehavioral symptoms of Rett syndrome, which, if approved, would be the first treatment of its kind in Europe, enhancing market opportunities.
- Investor Attention: Despite a 12.2% surge in stock price today, bringing it close to its 52-week high, some investors may be concerned about a potential pullback, suggesting that risk-tolerant investors might wait for stabilization before entering the stock.
See More
Acadia Appoints New Chief People Officer
- Executive Appointment: Acadia Pharmaceuticals announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6, aimed at advancing the company's global people and culture strategy to support its growth in the neurological and rare disease sectors.
- Extensive Industry Experience: Carl brings over 25 years of global HR leadership experience, having served as Senior Vice President at Merck, supporting a $50 billion global business, showcasing his capability in driving transformation within complex, science-driven organizations.
- Talent Strategy Leadership: During his tenure at Merck, Carl was responsible for global talent strategy and leadership development, successfully driving organizational capability shifts that included hiring over 10,000 employees annually, demonstrating his deep expertise in talent management.
- Strategic Culture Building: Carl expressed excitement about joining Acadia at this critical growth stage, looking forward to collaborating with the leadership team to strengthen company culture, develop talent, and support ongoing success while advancing innovation and patient care.
See More
U.S. Stocks Close Lower on Friday, Chipmakers Weigh on Market
- Market Decline: The S&P 500 and Nasdaq 100 fell by 0.05% and 1.09% respectively on Friday, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which could undermine investor confidence.
- Chipmaker Sell-off: The significant drop in Samsung Electronics and SK Hynix shares led to a more than 5% decline in South Korea's Kospi Index, triggering a global downturn in semiconductor stocks and exacerbating market uncertainty.
- Oil Price Impact: WTI crude oil prices fell over 3% to a four-month low on Friday, which helps lower inflation expectations and supports the stock market, but also reflects potential slowdowns in global economic growth.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward by 0.6 to 49.5, although still below the expected 50.0, indicating a cautious consumer outlook that may affect future spending.
See More
US Stock Market Under Pressure as Chip Stocks Plummet
- Market Weakness: The S&P 500 and Nasdaq 100 indices fell by 0.07% and 0.75%, respectively, reaching two-week lows, indicating market sensitivity to the weak performance of chipmakers, which may lead to declining investor confidence.
- Chip Stock Plunge: The significant sell-off of Samsung Electronics and SK Hynix caused the South Korean Kospi index to drop over 5%, triggering a global decline in chip stocks and exacerbating market uncertainty.
- Oil Price Decline Impact: WTI crude oil prices fell by more than 3%, easing inflation expectations and supporting stocks; however, the recovery of crude exports to 75% of pre-war levels may influence future market dynamics.
- Consumer Sentiment Revision: The University of Michigan's consumer sentiment index was revised upward to 49.5, although still below the expected 50.0, reflecting cautious consumer attitudes towards the economic outlook, which could affect retail and consumer-related stocks.
See More
Acadia's Daybue Receives Positive Recommendation in EU
- Drug Approval Progress: Acadia Pharmaceuticals' Daybue received a positive opinion from the CHMP upon reevaluation, recommending it for patients aged five and older with Rett syndrome; if approved by the European Commission, it would be the first treatment specifically for this rare condition in the region.
- Strong Market Reaction: Following the positive recommendation, Acadia's shares surged 15% on Friday, and if gains hold, it is on track for its best single-day performance since May 2025, indicating strong investor confidence in the drug's prospects.
- Clinical Trial Challenges: Despite showing some improvement in patients after 12 weeks of treatment, the CHMP's initial opinion in February deemed the benefits insufficiently significant and difficult to interpret, prompting Acadia to request a formal re-examination of the findings.
- Retail Investor Sentiment: Over the past 24 hours, retail sentiment around ACAD stock remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', and discussions surged 400% in the last week, reflecting optimism about Acadia's future potential.
See More
Acadia Pharmaceuticals Shares Surge 12.2% on Positive Drug News
- Strong Price Recovery: Acadia Pharmaceuticals saw its stock price surge 12.2% on Friday, bringing it close to its 52-week high, reflecting optimistic market sentiment regarding its future performance.
- New Market Opportunity: With the European Medicines Agency's recommendation, the Daybue drug is poised to become the first approved treatment for neurobehavioral symptoms of Rett syndrome, potentially opening new market avenues and driving sales growth.
- Solid Financial Performance: Acadia's Daybue and Nuplazid generated revenues of $101 million and $167 million respectively in Q1 2023, demonstrating the company's profitability and market potential in the rare disease sector.
- Investor Considerations: Despite the significant stock price increase, some investors may be concerned about short-term pullback risks, suggesting that risk-tolerant investors might wait for price stabilization before entering the market.
See More
Acadia Pharmaceuticals Shares Surge 12.2% on Positive Drug News
- Significant Market Potential: Acadia Pharmaceuticals focuses on rare diseases, where despite small market sizes, the lack of competition makes its potential revenue significant compared to its market cap of less than $5 billion, indicating a unique investment opportunity.
- Sales Growth: In the first fiscal quarter, Acadia's treatments Daybue and Nuplazid generated revenues of $101 million and $167 million respectively, reflecting a 20% year-over-year growth and showcasing the company's strong performance in the rare disease treatment sector.
- EU Approval Recommendation: The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Daybue for treating neurobehavioral symptoms of Rett syndrome, which, if approved, would be the first treatment of its kind in Europe, enhancing market opportunities.
- Investor Attention: Despite a 12.2% surge in stock price today, bringing it close to its 52-week high, some investors may be concerned about a potential pullback, suggesting that risk-tolerant investors might wait for stabilization before entering the stock.
See More
